Results 61 to 70 of about 342 (145)

Image_1_Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.tif

, 2022
BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Fengxia Hu (5745692), Xiaojing Kang (3931046), Maoli Dan (12459273), Qian Wang (32718), Yongzhen Hong (12459282), Junqin Liang (12459270), Yingbing Sang (12459276), Kailibinuer Abulikemu (12459279)   +7 more
core   +1 more source

Model‐informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1744-1759, June 2026.
Abstract Aims Population pharmacokinetic (popPK) and pharmacokinetic‐pharmacodynamic (PK/PD) models were developed to support clinical development of nemolizumab, a humanized monoclonal antibody targeting the IL‐31 receptor α, in adolescents and adults with moderate‐to‐severe atopic dermatitis (AD).
Floris Fauchet, Anna Largajolli, Petra M. Jauslin, Emilie Schindler, Mourad Hamimed, Wannee Kantasiripitak, Antonio Gonçalves, Eline Van Maanen, Khaled Benkali, Tomohisa Saito, Jonathan I. Silverberg, Andreas Wollenberg, Michael Graeber, Liliana Ulianov, Christophe Piketty, Luca Loprete, Vincent Duval, Nathalie Wagner   +17 more
wiley   +1 more source

Bullous Pemphigoid that Developed During Nemolizumab Treatment for Atopic Dermatitis: Two Case Reports

Acta Dermato-Venereologica
is missing (Short communication)
Michie Katsuta, Ryoichi Kamide, Yozo Ishiuji, Yoshimasa Nobeyama, Akihiko Asahina   +4 more
doaj   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, Volume 67, Issue 4, Page 191-199, June 2026.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

672 - Nemolizumab monotherapy improves itch, sleep disturbance, and skin lesions in patients with moderate-to-severe prurigo nodularis: Pooled analyses from OLYMPIA 1 and OLYMPIA 2 phase 3 studies

Introduction Nemolizumab demonstrated clinically and statistically significant improvements in itch, sleep disturbance, and skin lesions in adults with moderate-to-severe prurigo nodularis (PN) in two phase 3 pivotal studies (OLYMPIA 1 [NCT04501666]1 and
Ahmed, Faiz, Sofen, Howard, Kwatra, Shawn G, Piketty, Christophe, Ständer, Sonja, Jabbar Lopez, Zarif K, Metz, Martin, Pink, Andrew E, Yosipovitch, Gil, Silverberg, Jonathan I, Noda, Aliene   +10 more
core   +1 more source

Recent advances in treatment of prurigo nodularis

Dermatologica Sinica
Prurigo nodularis is a chronic skin condition which has significant negative impacts on the psychosocial function and quality of life of affected patients.
Chieh-Hsun Chen, Stephen Chu-Sung Hu
doaj   +1 more source

A Case of Erythema Multiforme Following the Administration of Nemolizumab

Cureus
Prurigo nodularis (PN) is a chronic inflammatory skin disorder characterized by intensely pruritic nodules. The pathogenesis of PN involves immune dysregulation, with a predominance of T helper (Th2)-type inflammation, including interleukin (IL)-4, IL-5, IL-13, and IL-31. Nemolizumab, an IL-31 receptor A inhibitor, was newly approved for PN in 2024. We
Mima, Yoshihito, Ohtsuka, Tsutomu
openaire   +2 more sources

Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial

Prurigo nodularis (PN) is a chronic and debilitating skin condition, characterized by intense itch with multiple nodular lesions. Nemolizumab demonstrated significant improvements in itch and skin nodules in adults with moderate to severe PN in a ...
Naldi, Luigi, Augustin, Matthias, Metelitsa, Andrei, Legat, Franz J, Fargnoli, Maria Concetta, Fage, Simon, Wollenberg, Andreas, Reich, Adam, Piketty, Christophe, Ständer, Sonja, Paul, Carle, Metz, Martin, Sundaram, Hema, Skov, Lone, Simon, Dagmar, Weisshaar, Elke, Sofen, Howard, Tsianakas, Athanasios, Jabbar-Lopez, Zarif K, Pink, Andrew, Korman, Neil J, Micali, Giuseppe, Kwatra, Shawn G, Chen, Xiaoxiao, OLYMPIA 1 Investigators, Yosipovitch, Gil, Homey, Bernhard, Parodi, Aurora, Lane, Joshua, Gordon, Kathleen Pieroni, Ladoyanni, Evmorfia, Podda, Maurizio, Fekete, Aniko Maria Dobribanne, Beattie, Paula, Woseth, Douglas M., Krishna, Sheila, Toth, Mariann, Goebeler, Matthias, Ruëff, Franziska, Anadkat, Milan J., Wolnik-Trzeciak, Grazyna, Almadi, Tamas, Helfrich, Yolanda, Kwatra, Shawn G., Slugocki, Rafal, Wohlrab, Johannes, Korman, Neil J., Jabbar-Lopez, Zarif K., Thaçi, Diamant, Parish, Jennifer L., Zink, Alexander, Buhl, Timo, Feliciani, Claudio, Sivamani, Raja, Weiss, Eduardo T., Plotkin, Adam, null, null, Yamauchi, Paul Steven, Maintz, Laura, Yazdi, Amir, Renczynska-Matysko, Joanna, Herzog, Rebeca, Stingeni, Luca, Goldman, Mitchel, Reich, Kristian, Stone, Melody L., Snyder, Robert A., Ling, Mark Russell, Lasagni, Claudia, Amerio, Paolo, Fuxench, Zelma C. Chiesa, Guenther, Lyn C. C., Galus, Ryszard, Gerdes, Sascha, Kolodziej, Tomasz, Cristaudo, Antonio, Gadzia, Joseph E., Legat, Franz J., Zakrzewski, Marcin, Janowicz, Anna, Elewski, Boni E., Volc, Sebastien, Peris, Ketty, Lam, Yaohan Adrienne, Patsinakidis, Nikolaos, Caban, Francis, Teller, Craig, Staubach-Renz, Petra, Sieniawska, Joanna, Muglia, Jennie J., Holzer, Gregor, Zook, Matthew Brent, Draelos, Zoe Diana, Lajos, Kemeny, Cohen, David, Pedrozo, Alejandro, Groysman, Vlada, Kuzmina, Natalia, Meggitt, Simon Jon, Argenziano, Guiseppe, Primka, Edward J., Holmes, Faith L., Sticherling, Michael, Walker, Kirsten Ann, Sepp, Norbert   +104 more
core   +1 more source

From Sprinters to Marathoners: Rethinking Therapeutic Speed and Disease Modification in Atopic Dermatitis

Allergy, Volume 81, Issue 7, Page 2565-2567, July 2026.
Thomas Bieber, Felix Lauffer
wiley   +1 more source

Randomized evidence breadth and comparative maturity of systemic targeted therapies for prurigo nodularis: a time-aligned systematic review and network meta-analysis

Journal of Dermatological Treatment
Objectives Randomized evidence for systemic targeted therapies in prurigo nodularis (PN) has expanded, but cross-trial differences limit valid comparison.
Yanchen Liu, Haoran Hu, Linfeng Li
doaj   +1 more source